Vectors Research Management’s Cadrenal Therapeutics CVKD Stock Holding History

Vectors Research Management’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.4K	Buy	+19,837	New	+$36K	0.01%	143

Other funds holding CVKD

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Quest 10 Wealth Builders Fuquay-Varina, Virginia $135M AUM 16.01% 1-Year Est. Return

Archer Investment Corporation Carmel, Indiana $545M AUM 21.2% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Vectors Research Management's CVKD Position: Q3 2026 in Review

Vectors Research Management opened a new position in Cadrenal Therapeutics (CVKD) in Q3 2026: 19,837 shares worth $21.4K. The stake represents 0.01% of the portfolio and ranks #143 among its holdings.

13 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

Vectors Research Management held 19,837 shares of Cadrenal Therapeutics worth $21.4K as of Q3 2026.
Cadrenal Therapeutics was a new Vectors Research Management position in Q3 2026.
Cadrenal Therapeutics made up 0.01% of Vectors Research Management's portfolio in Q3 2026, its #143 holding.
13 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Vectors Research Management's 13F filing for Q3 2026, filed 9 Nov 2026.